White Biotech New Drug Co., Ltd. Q4 2025 Financials
Key facts
- White Biotech New Drug Co., Ltd. Q4 2025 Financials
- White Biotech New Drug Co., Ltd. reported a basic earnings per share of -0.29 NTD, operating revenue of 135 million NTD, and a net loss after tax of 110 million NTD for Q4 2025.
- Source: PR Times
- Date: December 1, 2025
Direct answer
White Biotech New Drug Co., Ltd. reported a basic earnings per share of -0.29 NTD, operating revenue of 135 million NTD, and a net loss after tax of 110 million NTD for Q4 2025.
- Citation
- White Biotech New Drug Co., Ltd. Q4 2025 Financials (December 1, 2025), PR Times
- Source
- PR Times
- Date
- December 1, 2025
White Biotech New Drug Co., Ltd. reported a basic earnings per share of -0.29 NTD, operating revenue of 135 million NTD, and a net loss after tax of 110 million NTD for Q4 2025.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Company Code: 4108 Company Name: White Biotech New Drug Co., Ltd. Industry: Biotechnology and Medical Industry Year/Quarter: 2025 Q4 Basic Earnings Per Share: -0.29 NTD Operating Revenue: 135 million NTD Net Profit After Tax: -110 million NTD
FAQ
What are the key facts in this article?
White Biotech New Drug Co., Ltd. reported a basic earnings per share of -0.29 NTD, operating revenue of 135 million NTD, and a net loss after tax of 110 million NTD for Q4 2025.
What is the direct answer?
White Biotech New Drug Co., Ltd. reported a basic earnings per share of -0.29 NTD, operating revenue of 135 million NTD, and a net loss after tax of 110 million NTD for Q4 2025.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-4108-2025Q4 | December 1, 2025